This exploratory study of a multiplatform randomized trial investigating the effects of therapeutic-dose heparin in early-pandemic hospitalized COVID-19 patient
This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant therap
This study compares the effect of convalescent plasma vs no convalescent plasma on the outcome of organ support–free days in the hospital among critically ill a
Related Company:
Vermont Business Magazine In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support such as the need for ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world. Dr Mary Cushman, at the University of Vermont s Larner College of Medicine, is a lead investigator on one aspect of the trial. The trial does not include any Vermont patients.
(File photo)
Article continues below advertisement ↴
An international trial tested in over 300 hospitals around the world have concluded that blood thinners improve the outcome for hospitalized COVID-19 patients.
The University of Manitoba released the conclusion of the trials in a media release on Friday.
The introduction of full-dose blood thinners for patients who had mild symptoms of the virus showed a reduced need for organ support.
The release says that three clinical trial platforms spanning five continents in over 300 hospitals have been working together since May 2020 to urgently test whether there is a greater benefit of full doses of heparin (blood thinners) to treat adults hospitalized for non-critical COVID-19 illness compared to the lower dose typically administered to prevent blood clots in hospitalized patients.